Wasana Prasitsuebsai1, Sirinya Teeraananchai, Thida Singtoroj, Khanh Huu Truong, Jintanat Ananworanich, Viet Chau Do, Lam Van Nguyen, Pope Kosalaraksa, Nia Kurniati, Tavitiya Sudjaritruk, Kulkanya Chokephaibulkit, Stephen J Kerr, Annette H Sohn. 1. *HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand;†TREAT Asia/amfAR-The Foundation for AIDS Research, Bangkok, Thailand;‡Infectious Disease Department, Children's Hospital 1, Ho Chi Minh City, Vietnam;§US Military HIV Research Program, Walter Reed Army Institute of Research/Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD;‖Infectious Disease Department, Children's Hospital 2, Ho Chi Minh City, Vietnam;¶Infectious Disease Department, National Hospital of Pediatrics, Hanoi, Vietnam;#Division of Infectious Diseases, Department of Pediatrics, Khon Kaen University, Khon Kaen, Thailand;**Cipto Mangunkusumo General Hospital, Jakarta, Indonesia;††Faculty of Medicine and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand;‡‡Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand;§§The Kirby Institute, University of New South Wales, Sydney, Australia; and‖‖Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
Abstract
BACKGROUND: Data on pediatric treatment outcomes and drug resistance while on second-line antiretroviral therapy (ART) are needed to guide HIV care in resource-limited countries. METHODS: HIV-infected children <18 years who were switched or switching to second-line ART after first-line failure were enrolled from 8 sites in Indonesia, Thailand, and Vietnam. Genotyping was performed at virologic failure (VF; HIV-RNA >1000 copies/mL). Cox proportional hazards regression was used to evaluate factors predicting VF. RESULTS: Of 277 children, 41% were female. At second-line switch, age was 7.5 (5.3-10.3) years, CD4 count was 300 (146-562) cells per cubic millimeter, and percentage was 13 (7-20%); HIV-RNA was 5.0 (4.4-5.5) log10 copies per milliliter. Second-line regimens contained lamivudine (90%), tenofovir (43%), zidovudine or abacavir (30%), lopinavir (LPV/r; 91%), and atazanavir (ATV; 7%). After 3.3 (1.8-5.3) years on second-line ART, CD4 was 763 (556-1060) cells per cubic millimeter and 26% (20-31%). VF occurred in 73 (27%), with an incidence of 7.25 per 100 person-years (95% confidence interval [CI]: 5.77 to 9.12). Resistance mutations in 50 of 73 children with available genotyping at first VF included M184V (56%), ≥1 thymidine analogue mutation (TAM; 40%), ≥4 TAMs (10%), Q151M (4%), any major LPV mutation (8%), ≥6 LPV mutations (2%), and any major ATV mutation (4%). Associations with VF included age >11 years (hazard ratio [HR] 4.06; 95% CI: 2.15 to 7.66) and HIV-RNA >5.0 log10 copies per milliliter (HR 2.42; 95% CI: 1.27 to 4.59) at switch and were seen more commonly in children from Vietnam (HR 2.79; 95% CI: 1.55 to 5.02). CONCLUSIONS: One-fourth of children developed VF while on second-line ART. However, few developed major mutations to protease inhibitors.
BACKGROUND: Data on pediatric treatment outcomes and drug resistance while on second-line antiretroviral therapy (ART) are needed to guide HIV care in resource-limited countries. METHODS:HIV-infectedchildren <18 years who were switched or switching to second-line ART after first-line failure were enrolled from 8 sites in Indonesia, Thailand, and Vietnam. Genotyping was performed at virologic failure (VF; HIV-RNA >1000 copies/mL). Cox proportional hazards regression was used to evaluate factors predicting VF. RESULTS: Of 277 children, 41% were female. At second-line switch, age was 7.5 (5.3-10.3) years, CD4 count was 300 (146-562) cells per cubic millimeter, and percentage was 13 (7-20%); HIV-RNA was 5.0 (4.4-5.5) log10 copies per milliliter. Second-line regimens contained lamivudine (90%), tenofovir (43%), zidovudine or abacavir (30%), lopinavir (LPV/r; 91%), and atazanavir (ATV; 7%). After 3.3 (1.8-5.3) years on second-line ART, CD4 was 763 (556-1060) cells per cubic millimeter and 26% (20-31%). VF occurred in 73 (27%), with an incidence of 7.25 per 100 person-years (95% confidence interval [CI]: 5.77 to 9.12). Resistance mutations in 50 of 73 children with available genotyping at first VF included M184V (56%), ≥1 thymidine analogue mutation (TAM; 40%), ≥4 TAMs (10%), Q151M (4%), any major LPV mutation (8%), ≥6 LPV mutations (2%), and any major ATV mutation (4%). Associations with VF included age >11 years (hazard ratio [HR] 4.06; 95% CI: 2.15 to 7.66) and HIV-RNA >5.0 log10 copies per milliliter (HR 2.42; 95% CI: 1.27 to 4.59) at switch and were seen more commonly in children from Vietnam (HR 2.79; 95% CI: 1.55 to 5.02). CONCLUSIONS: One-fourth of children developed VF while on second-line ART. However, few developed major mutations to protease inhibitors.
Authors: Moses R Kamya; Harriet Mayanja-Kizza; Andrew Kambugu; Sabrina Bakeera-Kitaka; Fred Semitala; Patricia Mwebaze-Songa; Barbara Castelnuovo; Petra Schaefer; Lisa A Spacek; Anne F Gasasira; Elly Katabira; Robert Colebunders; Thomas C Quinn; Allan Ronald; David L Thomas; Adeodata Kekitiinwa Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Victor Musiime; Elizabeth Kaudha; Joshua Kayiwa; Grace Mirembe; Matthew Odera; Hilda Kizito; Immaculate Nankya; Francis Ssali; Cissy Kityo; Robert Colebunders; Peter Mugyenyi Journal: AIDS Res Hum Retroviruses Date: 2013-01-11 Impact factor: 2.205
Authors: Habib O Ramadhani; John A Bartlett; Nathan M Thielman; Brian W Pence; Stephen M Kimani; Venance P Maro; Mtumwa S Mwako; Lazaro J Masaki; Calvin E Mmbando; Mary G Minja; Eileen S Lirhunde; William C Miller Journal: Open Forum Infect Dis Date: 2014-09-09 Impact factor: 3.835
Authors: Ragna S Boerma; Torsak Bunupuradah; Dorothy Dow; Joseph Fokam; Azar Kariminia; Dara Lehman; Cissy Kityo; Victor Musiime; Paul Palumbo; Annelot Schoffelen; Sam Sophan; Brian Zanoni; Tobias F Rinke de Wit; Job C J Calis; Kim C E Sigaloff Journal: J Int AIDS Soc Date: 2017-09-15 Impact factor: 5.396
Authors: Kyoung Hwa Lee; Ji Un Lee; Nam Su Ku; Su Jin Jeong; Sang Hoon Han; Jun Yong Choi; Young Goo Song; June Myung Kim Journal: Yonsei Med J Date: 2017-07 Impact factor: 2.759
Authors: Oliver T Stirrup; David T Dunn; Anna Tostevin; Caroline A Sabin; Anton Pozniak; David Asboe; Alison Cox; Chloe Orkin; Fabiola Martin; Patricia Cane Journal: AIDS Res Ther Date: 2018-04-16 Impact factor: 2.250